EPO Patent: New Therapeutic Combinations for Progressive Fibrosing Lung Diseases

The European Patent Office has published patent application EP4520394A2 concerning new therapeutic combinations for treating progressive fibrosing interstitial lung diseases. The patent was filed by Boehringer Ingelheim International GmbH and lists multiple inventors. The publication date is March 18, 2026.

EPO Patent Publication: Enhancing Vaccine Immunogenicity

The European Patent Office has published patent application EP4509185A2 concerning methods for enhancing the immunogenicity of vaccines using oral yeast beta-glucans. The patent application lists Memorial Sloan Kettering Cancer Center as the applicant.

EPO Patent: Kinase Inhibitors for Nervous System Disorders

The European Patent Office has published patent application EP4574153A2 concerning kinase inhibitors for treating central and peripheral nervous system disorders. The patent application lists the University of Miami as the applicant and includes specific IPC classifications related to chemical compounds and their therapeutic applications.

Bifidobacterium breve strain composition for preventing skin allergies

The European Patent Office has published patent application EP4574160A1 concerning a composition containing Bifidobacterium breve strain for preventing skin allergies. The patent application was filed by Hipp & Co and lists several inventors. The publication date is March 18, 2026.

EPO Patent for GnRH Antagonist Dosing Regimens for Uterine Fibroids

The European Patent Office has published a patent (EP4509173A2) for Kissei Pharmaceutical Co., Ltd. concerning GnRH antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss. The patent details specific treatment protocols and is effective from March 18, 2026.

Oak Hill Bio Patent: Compositions for Neonates

The European Patent Office has published patent EP4534073A2 for Oak Hill Bio Limited, detailing compositions suitable for use in neonates. This publication relates to therapeutic compositions and their potential applications in treating conditions in newborns.

EPO Patent Promotes Hypoxia for Treating Mitochondrial Dysfunction

The European Patent Office has published patent application EP4512819A2, detailing compositions and methods that promote hypoxia for treating mitochondrial dysfunction and oxidative stress disorders. The patent is assigned to The General Hospital Corporation and Massachusetts Institute of Technology.

Chemotherapeutic Drug Implant Patent Filing by CRISM THERAPEUTICS LTD

The European Patent Office has published a patent application (EP4548920A2) filed by CRISM THERAPEUTICS LTD for a chemotherapeutic drug implant. The patent application details include the applicant, inventors, and IPC classifications related to drug formulation and administration.

New Therapeutic Combinations for Progressive Fibrosing Lung Diseases

The European Patent Office published a new patent application (EP4494701A2) for therapeutic combinations for treating progressive fibrosing interstitial lung diseases. The applicant is Boehringer Ingelheim International GmbH. The patent is designated for multiple European states.

EPO Patent Publication: Therapeutic Agents for Neurodegenerative Diseases

The European Patent Office has published patent application EP4467195A2 concerning therapeutic agents for neurodegenerative diseases, filed by IntraBio Ltd. This publication details specific chemical compounds and their intended medical applications.